For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a slightly increased risk for incident diabetic retinopathy (DR) and with a ...

US pharma major Eli Lilly’s shares rose 2.6% to $713.69 in early trading today, after it released positive top-line results ...

Patients with type 2 diabetes and atopic dermatitis show higher risk for cardiovascular events, but GLP-1 agonists reduce the ...

A NEW drug developed to combat diabetes and obesity melts fat at double the rate of other GLP-1 drugs, scientists say. The ...

The latest results from a trial of a pill form popular GLP-1 medications offer enough information for the Eli Lilly to request global regulatory approval this year, the company said Tuesday.

GLP-1 receptor agonists that are prescribed once weekly, such as semaglutide, dulaglutide, and long-acting release exenatide, are inactive and half-way eliminated in 5 to 7 days.

The findings suggest that while GLP-1 RAs may slightly raise the risk of developing diabetic retinopathy, they do not ...

The only safety endpoint associated with GLP-1 receptor agonist use was a 49% increased risk of diabetic retinopathy (aHR, 1.49; 1.11-2.00; P =.008).

GLP-1 RA therapy reduces hidradenitis suppurativa severity, flares, symptoms, and BMI in patients with hidradenitis ...

Lixisenatide is an analog of exenatide, which was the first GLP-1 receptor agonist. Lixisenatide is administered once a day, but it doesn’t have a 24-hour duration of action.

Among 24,103 individuals dispensed a GLP-1 receptor agonist between 2012 and 2021, 8083 were dispensed antidepressants in 2022 (odds ratio, 1.52).

GLP-1 receptor agonists are linked to a 55% reduction in mortality risk in women with ovarian cancer, based on a retrospective cohort study. The study utilized data from the TriNetX Research ...